Negative results were reported by a randomized, double-blind, placebo-controlled, flexible doses (40-120 mg/day) study of levomilnacipran ER for MDD; although levomilnacipran ER-treated patients demonstrated greater reduction in MADRS total score from baseline endpoint compared to placebo group, the difference from placebo did not reach statistical significance [ 32 ].
← all excerpts
The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
1
—
—